Detection and Quantification of BCR-ABL1 Fusion Transcripts by Droplet Digital PCR

Hughes, 2003, Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia, N Engl J Med, 349, 1423, 10.1056/NEJMoa030513 Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, 355, 2408, 10.1056/NEJMoa062867 Baccarani, 2006, Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet, Blood, 108, 1809, 10.1182/blood-2006-02-005686 Hughes, 2006, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results, Blood, 108, 28, 10.1182/blood-2006-01-0092 Branford, 1999, Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics, Br J Haematol, 107, 587, 10.1046/j.1365-2141.1999.01749.x Hughes, 2010, Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS), Blood, 116, 3758, 10.1182/blood-2010-03-273979 Press, 2006, BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML, Blood, 107, 4250, 10.1182/blood-2005-11-4406 Zhang, 2007, Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations, J Mol Diagn, 9, 421, 10.2353/jmoldx.2007.060134 Branford, 2006, Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia, Leukemia, 20, 1925, 10.1038/sj.leu.2404388 Branford, 2008, Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials, Blood, 112, 3330, 10.1182/blood-2008-04-150680 White, 2010, Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA, Blood, 116, e111, 10.1182/blood-2010-06-291641 Muller, 2009, Harmonization of molecular monitoring of CML therapy in Europe, Leukemia, 23, 1957, 10.1038/leu.2009.168 Baccarani, 2009, Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet, J Clin Oncol, 27, 6041, 10.1200/JCO.2009.25.0779 Ross, 2011, Minimal residual disease: the advantages of digital over analog polymerase chain reaction, Leuk Lymphoma, 52, 1161, 10.3109/10428194.2011.580481 Cross, 2012, Standardized definitions of molecular response in chronic myeloid leukemia, Leukemia, 26, 2172, 10.1038/leu.2012.104 Mahon, 2010, Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial, Lancet Oncol, 11, 1029, 10.1016/S1470-2045(10)70233-3 Ross, 2010, Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR, Leukemia, 24, 1719, 10.1038/leu.2010.185 Benjamini, 2013, Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience, Leuk Lymphoma Thielen, 2013, Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON), Eur J Cancer, 49, 3242, 10.1016/j.ejca.2013.06.018 Ross, 2013, Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study, Blood, 122, 515, 10.1182/blood-2013-02-483750 Yhim, 2012, Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response, Leuk Res, 36, 689, 10.1016/j.leukres.2012.02.011 Takahashi, 2012, Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia, Haematologica, 97, 903, 10.3324/haematol.2011.056853 Hardan, 2012, Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia, Cytokine, 57, 290, 10.1016/j.cyto.2011.11.018 Marin, 2010, Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib, J Clin Oncol, 28, 2381, 10.1200/JCO.2009.26.3087 Press, 2007, A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response, Clin Cancer Res, 13, 6136, 10.1158/1078-0432.CCR-07-1112 Press, 2009, Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib, Blood, 114, 2598, 10.1182/blood-2008-08-173674 Branford, 2004, Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations, Blood, 104, 2926, 10.1182/blood-2004-03-1134 George, 2013, Detection and quantification of chimerism by droplet digital PCR, Chimerism, 4, 102, 10.4161/chim.25400 Weaver, 2010, Taking qPCR to a higher level: analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution, Methods, 50, 271, 10.1016/j.ymeth.2010.01.003 Hindson, 2011, High-throughput droplet digital PCR system for absolute quantitation of DNA copy number, Anal Chem, 83, 8604, 10.1021/ac202028g Lun, 2008, Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma, Proc Natl Acad Sci U S A, 105, 19920, 10.1073/pnas.0810373105 Barrett, 2012, Digital PCR analysis of maternal plasma for noninvasive detection of sickle cell anemia, Clin Chem, 58, 1026, 10.1373/clinchem.2011.178939 Lo, 2007, Digital PCR for the molecular detection of fetal chromosomal aneuploidy, Proc Natl Acad Sci U S A, 104, 13116, 10.1073/pnas.0705765104 Hindson, 2013, Absolute quantification by droplet digital PCR versus analog real-time PCR, Nat Methods, 10, 1003, 10.1038/nmeth.2633 Farago, 2013, Digital PCR to determine the number of transcripts from single neurons after patch-clamp recording, Biotechniques, 54, 327, 10.2144/000114029 Sykes, 1992, Quantitation of targets for PCR by use of limiting dilution, Biotechniques, 13, 444 Pinheiro, 2012, Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification, Anal Chem, 84, 1003, 10.1021/ac202578x Jennings, 2012, Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease, Arch Pathol Lab Med, 136, 33, 10.5858/arpa.2011-0136-OA Press, 2013, BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia, J Mol Diagn, 15, 565, 10.1016/j.jmoldx.2013.04.007 Brown, 2011, Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale, Blood Cancer J, 1, e13, 10.1038/bcj.2011.10 Goh, 2011, Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay, Leuk Lymphoma, 52, 896, 10.3109/10428194.2011.555569 Bartley, 2010, Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia, Br J Haematol, 149, 231, 10.1111/j.1365-2141.2009.08071.x Sobrinho-Simoes, 2010, In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib, Blood, 116, 1329, 10.1182/blood-2009-11-255109 Mattarucchi, 2009, Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis, J Mol Diagn, 11, 482, 10.2353/jmoldx.2009.080150